Lion Point Capital’s NextCure NXTC Stock Holding History

Lion Point Capital’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,000	Closed	-$2.02M	–	39
2021 Q3	$2.02M	Hold	25,000	–	–	0.38%	32
2021 Q2	$2.41M	Hold	25,000	–	–	0.42%	25
2021 Q1	$3M	Hold	25,000	–	–	0.55%	23
2020 Q4	$3.27M	Buy	+25,000	New	+$3.23M	0.63%	19

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lion Point Capital's NXTC Position: Q4 2021 in Review

Lion Point Capital sold out of NextCure (NXTC) in Q4 2021, closing a stake of 25,000 shares — an estimated $2.02M sold.

Lion Point Capital first reported a position in NXTC in Q4 2020 and held it in 4 quarters. The position peaked at $3.27M in Q4 2020. 71 funds tracked by Wall St. Rank hold NXTC as of Q4 2021.

Lion Point Capital reported no remaining NextCure position as of Q4 2021 after selling out during the quarter.
Lion Point Capital sold 25,000 NextCure shares in Q4 2021, an estimated $2.02M.
Lion Point Capital first reported a position in NextCure in Q4 2020 and held it in 4 quarters.
Lion Point Capital's NextCure position peaked at $3.27M in Q4 2020.
71 funds tracked by Wall St. Rank held NextCure as of Q4 2021.

Based on Lion Point Capital's 13F filing for Q4 2021, filed 14 Feb 2022.